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Background: Explore the treatment of oral lichen planus with topical corticosteroids by the healthcare profession-
als in Spain.
Material and Methods: A questionnaire targeted health professionals who treat OLP, in particular maxillofacial 
surgeons, dermatologist and dentist. The dissemination of the questionnaires was conducted through professional 
associations and dental and medical societies. The questionnaire was previously evaluated by means of a cognitive 
pre-test procedure to ensure that the questions were opportune and appropriate, understandable and acceptable 
among the professionals.
Results: Of the 890 questionnaires sent a total of 190 questionnaires were answered by 90 dentists, 60 dermatol 
gists and 40 by maxillofacial surgeons. The most frequent treatment was 0.1%triamcinolone acetonide in orobase 
3 times a day. The effectiveness of the topical corticosteroid treatment was 6.68 (SD= 2.26) in a scale of 1 to 10. 
The 30% of the dentists and 10.49% of maxillofacial surgeons combined treatment with other drugs. The most 
frequent one (80%) was nystatin (100,000 IU per millimetre). Dermatologists did not use other treatments in co 
bination with corticosteroids
Conclusions: There is a need for national guidelines in treatment for oral lichen planus (treatment criteria, drug, 
dose, treatment time and method of application of corticosteroid) that can be applied by all professionals who treat 
this disease.
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Introduction
The term lichen planus (LP) was initially introduced by 
Erasmus Wilson in 1869 to redefine the condition that 
had been previously named leichen ruber by Hebra (1).
The first variant of LP was reported by Kaposi in 1892 
and the first description of the peculiar striae was made 
by Louis Frederick Wickham (2,3). The histological 
findings were elaborated by Darier in 1909 (4).
Lichen planus (LP) is a chronic autoimmune mucocu-
taneous condition which most commonly affects mid-
dleaged adults of both sexes with a slight predominance 
in women (ratio 1.4:1). LP can affect the oral mucosa, 
skin, genital mucosa, scalp and nails. The prevalence of 
oral lichen planus (OLP) in the general population rang-
es between 0.5-2.6% with variations between different 
countries: 0.5% in Japanese population, 1.9% in Swed-
ish population, 2.6% in the Indian population and 0.38% 
in Malaysian population (5-9). In Spain, the prevalence 
of LP was 0.2-2% (10).
Clinically we can observe four forms of OLP: reticular 
form, atrophic-erosive form, plaque form and papular 
form (5,11). Lesions are typically bilateral and burning 
sensation and sometimes pain usually accompany the 
erosive type lesion (12). Several factors have been pro-
posed for the aetiology of OLP including: genetic fac-
tors, dental materials, drugs, infectious agents, bacterial 
and viral infections, autoimmunity (autoimmune dis-
eases), immunodeficiency, food allergies, stress, habits, 
trauma, diabetes, malignant neoplasm and bowel dis-
eases (1,11-13). The pathogenesis of OLP includes anti-
gen-specific and non-specific mechanism. Antigenspe-
cific mechanism in OLP include antigen presentation by 
basal keratinocytes and antigen-specific keratinocyte 
killing by CD8+ cytotoxic T cells. Non-specific mecha-
nism include mast cell degranulation and matrix metal-
loproteinase activation in OLP lesions (13,14).
Several treatment regimens have been proposed to 
improve management of symptomatic OLP: corticos-
teroids, retinoids, immunosupressors (cyclosporine, le-
vamisole and azithioprine), antifungal agents and psor-
alen and ultraviolet A radiation (PUVA) therapy (15).
Topical treatment is generally preferred as it has fewer 
adverse effects. Systemic agents was indicated if lesions 
are disseminated and mainly involve the skin, mucosa 
or when topical therapies are not effective.
Topical corticosteroids are the most useful agents for the 
treatment of OLP but there is a lack of adequate studies 
determining their efficacy and optimal dose, duration 
of treatment and type of formulation (15-19). The aim of 
this article is to explore the different topical corticoster-
oids for the treatment OLP and compare treatment regi-
men according to the healthcare professionals in Spain.
A questionnaire has been developed and has been sent 
to healthcare professionals that treat OLP in Spain.
Material and Methods
In order to know the type of treatment used with topical 
corticosteroids for the treatment of oral lichen planus a 
questionnaire was sent by mail (web link) to healthcare
professionals in Spain.
- Measurement tool
A questionnaire targeted health professionals who treat
OLP, and in particular maxillofacial surgeons, derma-
tologist and dentist. The dissemination of the question-
naires was conducted through professional associations
and dental and medical societies. Anonymity in com-
pleting the questionnaire was sought in all cases. The 
link sent redirect participants to a website where the 
questionnaire was filled anonymously and later sent to 
a database.
The questionnaire was previously evaluated by means 
of a cognitive pre-test procedure to ensure that the 
questions were opportune and appropriate, understand-
able and acceptable among the professionals. This pilot 
survey was targeted to 10 dental professionals selected 
due to their accessibility and proximity to the investi-
gational team.
- Statistical analysis
The medical professional was the statistical unit of anal-
ysis. Frequency analysis was performed for categorical 
variables and mean ± standard deviation was calculated 
for continuous variable. The results were analyzed us-
ing SPSS v15.0 for Windows statistical software pack-
age (SPSS Inc., Chicago, IL, USA).
Results
- Participants
Of the 890 questionnaires sent a total of 190 (21.34%) 
questionnaires were answered and processed. Ninety 
questionnaires were answered by dentists, 60 by der-
matologists and 40 by maxillofacial surgeons. The 10%
of the professionals have an experience of 1-5 years, 
39.47% of 6-10 years, 10.1% of 11-15 years, 10% of 16- 
20 years, 8.42% of 21-25 years, 7.89% of 26-30 years 
and 13.15% of more than 30 years. The 90% of respond-
ents realize the diagnosis of OLP by clinical findings 
and biopsy. The remaining 10% used only the clinical 
findings. The most common treated form of OLP was 
the atrophic-erosive form (65%) followed by the retic-
ular form (22.12%) and the less treated form was the 
plaque form 12,88%).
- Topical corticosteroids
Type: The most frequent topical corticosteroids was 
triamcinolone acetonide (71.57%), followed by fluam-
cinolone acetonide (15.26%) and clobetasol propionate 
(12.10%). The data according to the medical professional 
were as the following: triamcinolone acetonide was used 
by in 78% of the dentists, fluamcinolone acetonide by 
14.23% and clobetasol propionate by 7.77% . Meanwhile, 
triamcinolone acetonide was used by e 60% of the derma-
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tologists, fluamcinolone acetonide by 20% and clobetasol 
propionate by 20%. Triamcinolone acetonide was used 
by 75% of the maxillofacial surgeons, fluamcinolone ac-
etonide by 15% and clobetasol propionate by 10%.
Mode of application: The most common mode was paste 
(62,63%). This mode of application was used by 55.56 
of the dentists, 66.66% of the dermatologists and 75% 
of the maxillofacial surgeons. The solution form was 
the second mode of application (35.26%). This mode of 
application was used by 44.44% of the dentists, 28.34% 
of the dermatologist and 25% of the maxillofacial sur-
geons. The less frequent mode of application was oily 
ointment (2.11%). This form of application was only 
used by 5% of the dermatologists.
Frequency and concentration: The daily regimen mostly 
employed was 3 times a day (46.60%) follow by two 
times a day (21.4%) and one single application (20%). 
Four times a day was the least frequent (12%). The daily 
dose prescribed by the medical professionals is detailed 
in Table 1 and the concentration of each corticosteroid 
in Table 2. The most frequent concentrations were 0.1% 
triamcinolone actonide, 0.05% fluamcinolone acetonide 
and 0.05% clobetasol propionate. Table 3 shows the re-
sults of combining the type of corticosteroid, dosage, 
mode of application and daily regimen. The most fre-
quent combination was 0.1%triamcinolone acetonide 
paste 3 times a day. The time for which this treatment 
had been maintained was variable. The 10% of profes-
sionals kept it for 15 days, the 15% for one month, the 
35% for 1.5 months and the remaining 40% for two 
months.
Efficacy: The effectiveness of the corticosteroid treat-
ment was scored in a scale of 1 to 10 (1 was no effec-
tiveness and 10 the most effective). The mean value of 
the evaluations were 6.68 (SD= 2.26). The evaluations 
by medical specialty are shown in figure. 1. The effec-
tiveness of triamcinolone acetonide 0.1% paste, 3 times 
a day (the most frequent combination), was rated 7.1 
(SD=1.18).
- Other treatments
The participants in the questionnaires were asked if 
they added other medicaments to the usual treatment 
with topical corticosteroids. The answer was Yes by 
40.49%, being 30% dentists and 10.49% maxillofacial 
surgeons. All dermatologists did not use other treat-
ments in combination with corticosteroids. The most 
frequent medicament (80%) was nystatin (100,000 IU 
per millimetre), followed by retinoid acid (15%) and hy-
aluronic acid (5%). Dentists only added nystatin to the 
treatment of OLP.
Discussion
A review of the scientific literature has revealed only 
one study similar to our own, exploring the treatment of 
oral lichen planus in Spain. In the study of Lóper-Jornet 
et al. (20) report a necessity of guidelines to treat oral 
lichen planus. The most frequent treatment reported, 
according to Lóper-Jornet et al. (20), was topical corti-
coids (25%), followed by mouthwashes such as triclosan 
(20%) or clorhexidine (20%). Systemic corticoids were 
used by 6% of respondents, immunosuppressors by 
2.6% and other treatments by 1.5%. (20) If we unificate
the employment of triclosan and clorhexidine in a sin-
gle group we can observe as there is a majority (40%) 
of professionals who treat the oral lichen planus with 
different drugs to corticosteroids, these being the first 
line of action according to the majority of the consulted 
studies (10-19).
Table 1: Daily regimen of application of corticosteroid by medical specialty.
Table 2: Corticosteroid and concentration.
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Fig. 1: Effectiveness of the corticosteroid treatment in a score of 1 to ten points by medical specialty.
Table 3: Corticosteroid, dosage, mode of application and daily regimen.
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The study methodology (mailed questionnaires) has 
been widely used, though the response rates elicited 
with this approach are highly variable. López-Jornet et 
al. (20) obtained a 74% response rate, Payne (21) ob-
tained a 71% response rate in a study centered on den-
tists, while Cowan et al. (22) recorded a 67% response 
rate. In contrast, Warnakulasuriya and Johnson docu-
mented a rate of only 16% (23). Our response rate was 
21.34%, similar to Warnakulasuriya and Johnson (23). 
This low response rate makes caution necessary in draw-
ing conclusions from the results obtained, and precludes 
extrapolation of the findings to the global population of 
health professionals who treat OLP. However, the data 
in this work represent, to the best of our knowledge, the 
first insight into how OLP is treated with topic corticos-
teroids by the Spanish health professionals.
Corticosteroids have been found to be the most predict-
able and successful agents in treatment of oral lichen 
planus. Topical application is the treatment of choice, as 
it can be effectively delivered to the lesion with minimal 
potential for systemic side effects (15-18). The efficacy 
of corticosteroids for treatment of OLP is mainly attrib-
uted to its anti-inflammatory and immunosuppressive 
actions (18). Many trials and formulations of corticos-
teroids have been used in the treatment of OLP. In the 
Cochrane review of placebo-controlled randomized 
clinical trials of treatments used for symptomatic OLP, 
there have been no trials comparing topical steroids 
with placebo. There are many trials comparing differ-
ent steroids with different alternative treatments (retin-
oids, immunosupressors -cyclosporine, levamisole and 
azithioprine-, and ultraviolet A radiation (PUVA) ther-
apy) and there is no evidence that one steroid treatment 
is better or worse than another (19).
In our study the most frequent treatment option was tri-
amcinolone acetonide 0.1%, orabase, 3 times a day. This 
treatment is the less employed by the most of the clini-
cal trials published in relation to corticosteroids treat-
ment of OLP (19). Yoke et al. (24) compare topical tri-
amcinolone acetonide 0.1% versus topical cyclosporine 
solution (100 mg/ml) in a randomized controlled trial. 
Clinical response, pain, burning sensation, area of re-
ticulation, erythema, and ulceration at week 4 were all 
worse in patients receiving cyclosporine than in those 
receiving steroid, however the differences were not sta-
tistically significant. There was a statistically significant 
reduction in the mean area of ulceration in the triamci-
nolone group. Laeijendecker (25) et al. have compared 
topical treatment of OLP with triamcinolone acetonide 
0.1% or
tacrolimus 0.1%. A better initial therapeutic response 
was assoicated with tacrolimus 0.1%, however relapses 
occurred frequently within 3-9 weeks of the cessation 
of treatment. Triamcinolone acetonide 0.1% in paste 
has been compared with betamethasone oral mini-pulse 
(OMP) therapy and the results indicated that topical tri-
amcinolone acetonide was equally effective (26). The 
same results has been obtained when triamcinolone ac-
etonide 0.1% has been compared to prednisolone 5 mg 
mucoadhesive tablet (27).
In fact, there is no clinical trials that have compared the 
effectiveness of different corticosteroids in the treat-
ment of OLP. However, triamcinolone acetonide was 
considered in several studies as the treatment of choice
with good results. In our study, the average rating for 
the effectiveness of treatment using triamcinolone ac-
etonide 0.1% , orabase, 3 times a day was 7.1 (SD=1.18), 
the overall scoring of the effectiveness of topical corti-
costeroids was 6.68 (SD= 2.26).
Finally, it is important to highlight the need for national 
guidelines of treatment for oral lichen planus that can 
be applied by all professionals who treat this disease. 
Thus, the treatment criteria are much clearer and simi-
lar patterns of drug, dose, treatment time and method of 
application of corticosteroid can be followed. The low 
response rate of the questionnaires limits the extrapola-
tion of the study outcomes to the management of OLP 
with topical corticosteroids in Spain. Moreover, there is 
a need for a scientific evidence of the effectiveness of 
topical corticosteroids in the symptomatic treatment of 
oral lichen planus.
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